Search Results

You are looking at 1 - 10 of 223 items for :

  • "Next-generation sequencing" x
  • Refine by Access: All x
Clear All
Full access

Alexandra O. Sokolova, Brian H. Shirts, Eric Q. Konnick, Ginger J. Tsai, Bernardo H.L. Goulart, Bruce Montgomery, Colin C. Pritchard, Evan Y. Yu, and Heather H. Cheng

Background Over the past decade, advances in next-generation sequencing (NGS) have decreased cost and enabled more widespread use in solid tumor oncology. This has been accompanied by increasing therapeutic options based on tumor genomic profiling

Full access

Tarra Evans and Ursula Matulonis

. Mardis ER . Next-generation DNA sequencing methods . Annu Rev Genomics 2008 ; 9 : 387 – 402 . 3. Hagemann IS Fuchs S Monoranu CM . Design of targeted, capture-based, next generation sequencing tests for precision cancer therapy . Cancer

Full access

Luxi Chen, John Davelaar, Srinivas Gaddam, Kambiz Kosari, Nicholas Nissen, George Chaux, Christopher Lee, Eric Vail, Andrew Hendifar, Jun Gong, Karen Reckamp, and Arsen Osipov

weeks following stent placement, the patient’s CA 19-9 level was 97 U/mL. At the time of initial diagnostic biopsy, next-generation sequencing (NGS) was obtained via Tempus Laboratories, Inc. Staging CT scan of the chest showed suspicious spiculated

Full access

Kristin K. Deeb, Jakub P. Sram, Hanlin Gao, and Marwan G. Fakih

mutation, such as KRAS , to a more comprehensive assessment of genomic alterations. This review describes next-generation sequencing (NGS)-based multigene assays in clinical practice, their distinct advantages, and their limitations. Application of

Full access

Christie Hancock and Jacob Bitran

Background: The value of next-generation sequencing (NGS) tests is dependent on how it changes clinical management, if at all. There are not any guidelines on when a physician should obtain testing; what certain genetic variations can be clinically

Full access

Andrew W. Hahn, Smith Giri, Dilan Patel, Heather Sluder, Ari Vanderwalde, and Mike G. Martin

small clinical trials. 5 The availability of next-generation sequencing (NGS) has made it feasible for clinicians to analyze genetic profiles of an individual's cancer. When these results are coupled with the continual development of targeted therapies

Full access

Kaushal Desai, Gillian Hooker, Gboyega Adeboyeje, Sumesh Kachroo, and Shuvayu Sankar Sen

Background: Next-Generation Sequencing (NGS) based genomic testing is one of the key drivers of precision medicine in US Oncology practices. Studies of utilization of NGS testing via insurance claims have been challenged by widely variable and

Full access

Szu-Chun Yang, Yi-Chen Yeh, Yi-Lin Chen, and Chao-Hua Chiu

for the treatment of patients with these gene alterations. Next-generation sequencing (NGS) can test all these actionable gene alterations and has emerged on the front line to guide appropriate therapy. In Western countries, where none of these 8

Full access

Natasha Hunter, Sarah Croessmann, Karen Cravero, Daniel Shinn, Paula J. Hurley, and Ben Ho Park

digital PCR (ddPCR) and ultra-deep next-generation sequencing (NGS), clinicians are able to track tumor burden, evaluate response to therapies, and detect MRD using cancer DNA alterations present in cfDNA as a biomarker. Indeed, many studies have supported

Full access

angioimmunoblastic T-cell lymphoma (AITL). Figure 1. Patient case study 1: results of further testing. Abbreviations: NGS, next-generation sequencing; RUL, right upper lobe; SUV, standard uptake value; VATS, video-assisted thoracic surgery. Dr. Advani explained that